Molecure S.A. (MOC) - Total Liabilities
Based on the latest financial reports, Molecure S.A. (MOC) has total liabilities worth zł9.24 Million PLN (≈ $2.54 Million USD) as of March 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Molecure S.A. - Total Liabilities Trend (2014–2024)
This chart illustrates how Molecure S.A.'s total liabilities have evolved over time, based on quarterly financial data. See working capital position of Molecure S.A. to evaluate short-term liquidity relative to the company's equity base.
Molecure S.A. Competitors by Total Liabilities
The table below lists competitors of Molecure S.A. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Level Biotechnology
TWO:3118
|
Taiwan | NT$237.03 Million |
|
Glacier Media Inc.
TO:GVC
|
Canada | CA$84.79 Million |
|
NovaBay Pharmaceuticals Inc
NYSE MKT:NBY
|
USA | $31.86 Million |
|
Redwood Group Ltd
TWO:8426
|
Taiwan | NT$1.27 Billion |
|
Latrobe Magnesium Limited
F:L2Q
|
Germany | €43.84 Million |
|
Seafire AB
ST:SEAF
|
Sweden | Skr524.00 Million |
|
SK Discovery Co Ltd
KO:006125
|
Korea | ₩8.93 Trillion |
|
Cnova NV
PA:CNV
|
France | €1.28 Billion |
Liability Composition Analysis (2014–2024)
This chart breaks down Molecure S.A.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Molecure S.A. stock valuation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 10.28 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.09 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.09 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Molecure S.A.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Molecure S.A. (2014–2024)
The table below shows the annual total liabilities of Molecure S.A. from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | zł10.31 Million ≈ $2.84 Million |
-9.09% |
| 2023-12-31 | zł11.34 Million ≈ $3.12 Million |
-2.31% |
| 2022-12-31 | zł11.61 Million ≈ $3.20 Million |
+11.16% |
| 2021-12-31 | zł10.45 Million ≈ $2.88 Million |
+3.49% |
| 2020-12-31 | zł10.09 Million ≈ $2.78 Million |
+53.94% |
| 2019-12-31 | zł6.56 Million ≈ $1.80 Million |
+59.00% |
| 2018-12-31 | zł4.12 Million ≈ $1.14 Million |
-14.91% |
| 2017-12-31 | zł4.85 Million ≈ $1.33 Million |
+93.30% |
| 2016-12-31 | zł2.51 Million ≈ $690.16K |
+129.40% |
| 2015-12-31 | zł1.09 Million ≈ $300.86K |
+95.19% |
| 2014-12-31 | zł560.05K ≈ $154.13K |
-- |
About Molecure S.A.
Molecure S.A., a biotechnology company, engages in discovering, developing, and commercializing therapeutics for neoplastic and inflammatory diseases in Poland. The company is involved in the development of OATD-01, a chitotriosidase/AMCASE inhibitor that has completed Phase I clinical trial for the treatment of sarcoidosis, as well as in preclinical stage to treat idiopathic pulmonary fibrosis a… Read more